Holger Thurm

First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer

Alice T. Shaw, Todd M. Bauer, Filippo de Marinis et al. · New England Journal of Medicine · 2020 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +16

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Benjamin Solomon, Benjamin Besse, Todd M. Bauer et al. · The Lancet Oncology · 2018 · 789 citations

Medicine, Oncology, Medical Oncology +10

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Nancy Y. Lee, Robert L. Ferris, Amanda Psyrri et al. · The Lancet Oncology · 2021 · 617 citations

Medicine, Oncology, Radiation Oncology +8

<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

Alice T. Shaw, Benjamin Solomon, Benjamin Besse et al. · Journal of Clinical Oncology · 2019 · 379 citations · Full text

Medicine, Oncology, Pharmacology +17

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial

Alice T. Shaw, Benjamin Solomon, Rita Chiari et al. · The Lancet Oncology · 2019 · 352 citations

Medicine, Oncology, Pharmacology +11